Radiation therapy and secondary malignancy in Li‐Fraumeni syndrome: A hereditary cancer registry study
| العنوان: | Radiation therapy and secondary malignancy in Li‐Fraumeni syndrome: A hereditary cancer registry study |
|---|---|
| المؤلفون: | Josh D. Schiffman, David K. Gaffney, Ying J. Hitchcock, Randa Tao, Yukun Luo, Wendy Kohlmann, Kristine E. Kokeny, Matthew M. Poppe, Peter G. Hendrickson, Luke Maese, Andrew J. Bishop, Shane Lloyd |
| المصدر: | Cancer Medicine Cancer Medicine, Vol 9, Iss 21, Pp 7954-7963 (2020) |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | p53, Male, 0301 basic medicine, Oncology, Cancer Research, Neoplasms, Radiation-Induced, Time Factors, medicine.medical_treatment, Germline, Li-Fraumeni Syndrome, 0302 clinical medicine, LFS, Risk Factors, Registries, Child, Li‐Fraumeni syndrome, Original Research, Neoplasms, Second Primary, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Treatment Outcome, Child, Preschool, 030220 oncology & carcinogenesis, Female, Hereditary Cancer, Adult, medicine.medical_specialty, Adolescent, Malignancy, lcsh:RC254-282, Risk Assessment, Young Adult, 03 medical and health sciences, Germline mutation, Internal medicine, RT‐induced malignancy, medicine, Humans, Genetic Predisposition to Disease, Radiology, Nuclear Medicine and imaging, Germ-Line Mutation, Retrospective Studies, Radiotherapy, business.industry, Infant, Newborn, Clinical Cancer Research, Infant, Secondary Malignancy, Histology, medicine.disease, United States, radiation, Radiation therapy, 030104 developmental biology, Li–Fraumeni syndrome, Neoplasm Recurrence, Local, Tumor Suppressor Protein p53, business |
| الوصف: | Background Li‐Fraumeni Syndrome (LFS) is a rare cancer‐predisposing condition caused by germline mutations in TP53. Conventional wisdom and prior work has implied an increased risk of secondary malignancy in LFS patients treated with radiation therapy (RT); however, this risk is not well‐characterized. Here we describe the risk of subsequent malignancy and cancer‐related death in LFS patients after undergoing RT for a first or second primary cancer. Methods We reviewed a multi‐institutional hereditary cancer registry of patients with germline TP53 mutations who were treated from 2004 to 2017. We assessed the rate of subsequent malignancy and death in the patients who received RT (RT group) as part of their cancer treatment compared to those who did not (non‐RT group). Results Forty patients with LFS were identified and 14 received RT with curative intent as part of their cancer treatment. The median time to follow‐up after RT was 4.5 years. Fifty percent (7/14) of patients in the curative‐intent group developed a subsequent malignancy (median time 3.5 years) compared to 46% of patients in the non‐RT group (median time 5.0 years). Four of seven subsequent malignancies occurred within a prior radiation field and all shared histology with the primary cancer suggesting recurrence rather than new malignancy. Conclusion We found that four of14 patients treated with RT developed in‐field malignancies. All had the same histology as the primary suggesting local recurrences rather than RT‐induced malignancies. We recommend that RT should be considered as part of the treatment algorithm when clinically indicated and after multidisciplinary discussion. Forty patients with LFS were identified and 14 received RT with curative intent as part of their cancer treatment. We found that four of 14 patients treated with RT developed in‐field malignancies. All had the same histology as the primary suggesting local recurrences rather than RT‐induced malignancies. |
| تدمد: | 2045-7634 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9254236bdccd7615f9d953009eb2f409Test https://doi.org/10.1002/cam4.3427Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9254236bdccd7615f9d953009eb2f409 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20457634 |
|---|